3'-Deoxy-3'-[F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2017 Oct 4

PMID 28971330

Citations 2

Authors

Sonja Schelhaas

Kathrin Heinzmann

Davina J Honess

Donna-Michelle Smith

Heather Keen

Sandra Heskamp

Timothy H Witney

Laurent Besret

Sabrina Doblas

John R Griffiths

Eric O Aboagye

Andreas H Jacobs

Affiliations

Soon will be listed here.

Abstract

Purpose: We recently reported that high thymidine phosphorylase (TP) expression is accompanied by low tumor thymidine concentration and high 3'-deoxy-3'-[F]fluorothymidine ([F]FLT) uptake in four untreated lung cancer xenografts. Here, we investigated whether this relationship also holds true for a broader range of tumor models.

Procedures: Lysates from n = 15 different tumor models originating from n = 6 institutions were tested for TP and thymidylate synthase (TS) expression using western blots. Results were correlated to [F]FLT accumulation in the tumors as determined by positron emission tomography (PET) measurements in the different institutions and to previously published thymidine concentrations.

Results: Expression of TP correlated positively with [F]FLT SUV (ρ = 0.549, P < 0.05). Furthermore, tumors with high TP levels possessed lower levels of thymidine (ρ = - 0.939, P < 0.001).

Conclusions: In a broad range of tumors, [F]FLT uptake as measured by PET is substantially influenced by TP expression and tumor thymidine concentrations. These data strengthen the role of TP as factor confounding [F]FLT uptake.

Citing Articles

F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma.

Crompton J, Armstrong W, Eckardt M, Seyedroudbari A, Tap W, Dry S J Nucl Med. 2021; 63(5):708-712.

PMID: 34593596 PMC: 9051595. DOI: 10.2967/jnumed.121.262502.

Exploring Solvent Effects in the Radiosynthesis of F-Labeled Thymidine Analogues toward Clinical Translation for Positron Emission Tomography Imaging.

Li J, Van Valkenburgh J, Conti P, Chen K ACS Pharmacol Transl Sci. 2021; 4(1):266-275.

PMID: 33615178 PMC: 7887844. DOI: 10.1021/acsptsci.0c00184.

References

Leyton J, Smith G, Lees M, Perumal M, Nguyen Q, Aigbirhio F . Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther. 2008; 7(9):3112-21. DOI: 10.1158/1535-7163.MCT-08-0264. View

Heinzmann K, Honess D, Lewis D, Smith D, Cawthorne C, Keen H . The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models. EJNMMI Res. 2016; 6(1):63. PMC: 4980847. DOI: 10.1186/s13550-016-0218-3. View

Schelhaas S, Heinzmann K, Bollineni V, Kramer G, Liu Y, Waterton J . Preclinical Applications of 3'-Deoxy-3'-[F]Fluorothymidine in Oncology - A Systematic Review. Theranostics. 2017; 7(1):40-50. PMC: 5196884. DOI: 10.7150/thno.16676. View

Li K, Rivory L, Clarke S . Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 820(1):121-30. DOI: 10.1016/j.jchromb.2005.03.008. View

Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra S . The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005; 32(3):257-63. DOI: 10.1007/s00259-004-1611-0. View

Heidebrecht F, Heidebrecht A, Schulz I, Behrens S, Bader A . Improved semiquantitative Western blot technique with increased quantification range. J Immunol Methods. 2009; 345(1-2):40-8. DOI: 10.1016/j.jim.2009.03.018. View

Bollineni V, Kramer G, Jansma E, Liu Y, Oyen W . A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016; 55:81-97. DOI: 10.1016/j.ejca.2015.11.018. View

Toyohara J, Fujibayashi Y . Trends in nucleoside tracers for PET imaging of cell proliferation. Nucl Med Biol. 2003; 30(7):681-5. DOI: 10.1016/s0969-8051(03)00084-2. View

Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, Chaplin D . Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102(11):1555-77. PMC: 2883160. DOI: 10.1038/sj.bjc.6605642. View

10.

van Waarde A, Cobben D, Suurmeijer A, Maas B, Vaalburg W, de Vries E . Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004; 45(4):695-700. View

11.

Chalkidou A, Landau D, Odell E, Cornelius V, ODoherty M, Marsden P . Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer. 2012; 48(18):3499-513. DOI: 10.1016/j.ejca.2012.05.001. View

12.

Lee S, Yeo J, Lee H, Lee E, Kim S, Jang S . Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014; 41(7):1327-35. DOI: 10.1007/s00259-014-2712-z. View

13.

Zhang C, Yan Z, Li W, Kuszpit K, Painter C, Zhang Q . [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells. Clin Cancer Res. 2011; 18(5):1303-12. DOI: 10.1158/1078-0432.CCR-11-1433. View

14.

Schelhaas S, Held A, Wachsmuth L, Hermann S, Honess D, Heinzmann K . Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer. Cancer Res. 2016; 76(24):7096-7105. DOI: 10.1158/0008-5472.CAN-16-1479. View

15.

Liekens S, Bronckaers A, Perez-Perez M, Balzarini J . Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol. 2007; 74(11):1555-67. DOI: 10.1016/j.bcp.2007.05.008. View

16.

Schelhaas S, Wachsmuth L, Viel T, Honess D, Heinzmann K, Smith D . Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging. J Nucl Med. 2014; 55(6):983-8. DOI: 10.2967/jnumed.113.133348. View

17.

Han J, Hong E, Lee S, Yoon S, Lee D, Lee J . Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol. 2005; 58(6):650-4. PMC: 1770682. DOI: 10.1136/jcp.2004.022764. View

18.

Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H . Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998; 4(4):1013-9. View

19.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T . XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22(11):2084-91. DOI: 10.1200/JCO.2004.11.069. View

20.

McKinley E, Ayers G, Smith R, Saleh S, Zhao P, Washington M . Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One. 2013; 8(3):e58938. PMC: 3598948. DOI: 10.1371/journal.pone.0058938. View